Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C

A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys®), With and Without Ribavirin (Copegus®) in Subjects With Hepatitis C

Compare the effectiveness of telaprevir (VX-950) in combination with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a) with and without Ribavirin (RBV) in reducing plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels

Inclusion Criteria:

• Hepatitis C virus Genotype 1 with detectable plasma hepatitis C virus RNA
• Have been infected with Hepatitis C virus for greater than (>) 6 months
• Seronegative for hepatitis B surface antigen and human immunodeficiency virus 1 and 2
• Must agree to use 2 methods of contraception, including 1 barrier method, during and for 24 weeks after the completion of the study (unless the subject is a female of documented non-child-bearing potential)
• Female subjects must have a negative pregnancy test at all visits before the first dose.

Exclusion Criteria:

• Received any approved or investigational drug or drug regimen for the treatment of hepatitis C.
• Any medical contraindications to Peg-IFN-alfa-2a or Ribavirin therapy
• Any other cause of significant liver disease in addition to hepatitis C; this may include but is not limited to, hepatitis B, drug or alcohol-related cirrhosis, autoimmune hepatitis, hemochromatosis, Wilson's disease, Nonalcoholic Steatohepatitis or primary biliary cirrhosis.
• Diagnosed or suspected hepatocellular carcinoma.
• Histologic evidence of hepatic cirrhosis (including compensated cirrhosis) based on a liver biopsy taken within 2 years before Study start.
• Alcohol/drug abuse or excessive use in the last 12 months.
• Participation in any investigational drug study within 90 days before drug administration or participation in more than 2 drug studies in the last 12 months (exclusive of the current study).